HIV‑1 drug‑resistance mutations and related risk factors among HIV‑1‑positive individuals receiving first-line antiretroviral therapy
Main Article Content
Abstract
Background
Acquired immunodeficiency syndrome (AIDS) remains a global health issue. Antiretroviral therapy (ART) controls HIV progression, but widespread use had led to drug resistance mutations (DRMs) such as M184V and K103N, compromising treatment efficacy. This study assessed the prevalence of these mutations and identified associated risk factors in patients with first-line nucleoside reverse transcriptase inhibitor (NRTI)-based ART.
Methods
A cross-sectional study was conducted involving 80 HIV patients aged > 18 years who had been on NRTI and non-NRTI (NNRTI) therapy for >6 months. Data included sociodemographic characteristics, ART adherence, opportunistic infections, viral load, CD4 count, treatment duration, ART regimen, and presence of M184V and/or K103N mutations. Genetic analysis was performed and statistical associations were assessed using simple and multivariate logistic regression.
Results
M184V and/or K103N mutations were detected in 8 patients (10%), significantly associated with poor ART adherence (p<0.01), detectable viral load (p<0.01) and male gender (p=0.048), but not with age (p=0.653), body mass index (p=0.661), opportunistic infections (p=0.938), CD4 count (p=0.265), and treatment duration (p=0.365). Multivariate logistic regression analysis showed that poor ART adherence was associated with a decreased risk of mutations compared to good adherence (OR = 0.73, 95% CI:0.012-0.427) and male patients had a 10-fold higher risk compared to females (OR = 10.03, 95% CI:1.033-97.350).
Conclusion
This study demonstrated that male gender was significantly associated with an increased risk of mutations, while poor ART adherence showed an unexpected inverse association. Strengthening adherence support programs remains essential to preventing drug resistance mutations and ensuring treatment efficacy.
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.
How to Cite
References
1. World Health Organization. HIV/AIDS fact sheet. Geneva: World Health Organization;2023.
2. Pusat Data dan Informasi Kementerian Kesehatan Republik Indonesia. Infodatin: situasi penyakit HIV AIDS di Indonesia. [Infodatin: the HIV AIDS situation in Indonesia]. Jakarta: 2020. Indonesian.
3. UNAIDS. 2025 AIDS targets; 2020. doi:10.18356/9789210055475c005.
4. World Health Organization (WHO). Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization;2015.
5. Kementerian Kesehatan Republik Indonesia. [Ministry of Health of the Republic of Indonesia]. Peraturan Menteri Kesehatan Republik Indonesia Nomor 23 Tahun 2022 Tentang Penanggulangan HIV, AIDS, Dan IMS. [Regulation of the Ministry of Health of the Republic of Indonesia No. 23 for the year 2022 on the control of HIV, AIDS, and STD.] 2022. Indonesian.
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services;2024.
7. Chris B, Anton P. HIV drug resistance-an emerging threat to epidemic control. N Engl J Med 2017;377:1605-7. doi:10.1056/NEJMp1710608.
8. Niu D, Tang H, Chen F, et al. Treatment failure and associated factors among people living with HIV on highly active antiretroviral therapy in mainland China: A systematic review and meta-analysis. PLoS ONE 2023;18:1-18. doi:10.1371/journal.pone.0284405.
9. Kurniawan F, Djauzi S, Yunihastuti E, Nugroho P. [Predictors of virological failure in patients with HIV on first-line ARV therapy and good drug adherence]. J Penyakit Dalam Indonesia 2017;4:29. Indonesian. doi:10.7454/jpdi.v4i1.110.
10. Fibriani A, Wisaksana R, Indrati A, et al. Virological failure and drug resistance during first line anti-retroviral treatment in Indonesia. J Med Virol 2013:1394-401. doi:10.1002/jmv.23606.
11. World Health Organization. HIV Drug resistance report 2021. Technical Report. Geneva: World Health Organization;2021.
12. Mziray SR, Kumburu HH, Assey HB, et al. Patterns of acquired HIV-1 drug resistance mutations and predictors of virological failure in Moshi, Northern Tanzania. PLoS One 2020;15:e0232649. doi: 10.1371/journal.pone.0232649.
13. Chen M, Wu M, Zeng L, et al. Virologic status and pattern of drug resistance mutation among ART-experienced HIV-infected patients in Butuo County, China. J Global Antimicrobial Resistance 2023;32:98-103. doi:10.1016/j.jgar.2023.01.002.
14. Zuo Z, Liang S, Sun X, et al. Drug resistance and virological failure among HIV-infected patients after a decade of antiretroviral treatment expansion in eight provinces of China. PLoS One 2016;11:1-13. doi:10.1371/journal.pone.0166661.
15. Zou X, He J, Zheng J, et al. Prevalence of acquired drug resistance mutations in antiretroviral-experiencing subjects from 2012 to 2017 in Hunan Province of central South China. Virol J 2020;17:1-9. doi:10.1186/s12985-020-01311-3.
16. Hauser A, Goldstein F, Reichmuth ML, et al. Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: systematic review and Bayesian evidence synthesis. J Clin Epidemiol 2022;148:135-45. doi: 10.1016/j.jclinepi.2022.02.005.
17. Miti S, Handema R, Mulenga L, et al. Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia. PLoS ONE 2020;15:1-15. doi:10.1371/journal.pone.0236156.
18. Metzner KJ, Leemann C, Di Giallonardo F, et al. Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection. PLoS ONE 2011;6:1-6. doi:10.1371/journal.pone.0021734.
19. Schaecher KL. The importance of treatment adherence in HIV. Am J Manag Care 2013;19:S231-7.
20. Seyed-Alinaghi SA, Afsahi AM, Moradi A, et al. Current ART, determinants for virologic failure and implications for HIV drug resistance: an umbrella review. AIDS Res Ther 2023;20:74. doi: 10.1186/s12981-023-00572-6.
21. Hutapea HML, Kridaningsih TN, Prasetyo KH, Antwi MB. Viral load as a risk factor of reverse transcriptase inhibitor drug resistance mutation in antiretroviral-treated people living with HIV/AIDS. Univ Med 2021;40:243-53. doi:10.18051/univmed.2021.v40.243-253.
22. Barnabas RV, Szpiro AA, van Rooyen H, et al. Community-based antiretroviral therapy versus standard clinic-based services for HIV in South Africa and Uganda (DO ART): a randomised trial. Lancet Global Health 2020;8:e1305-e15. doi:10.1016/S2214-109X(20)30313-2.
23. Derache A, Shin HS, Balamane M, et al. HIV drug resistance mutations in proviral DNA from a community treatment program. PLoS ONE 2015;10:1-14. doi:10.1371/journal.pone.0117430.
24. Luo X, Mo L, Su G, et al. Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy. J Pharmacol Sci 2019;139:275-79. doi:10.1016/j.jphs.2018.11.016.
25. Ganesan A, Hsieh HC, Chu X, et al. Low level viremia is associated with serious non-AIDS events in people with HIV. Open Forum Infect Dis 2024;11:1-9. doi:10.1093/ofid/ofae147.
26. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 3rd edition. Geneva: World Health Organization; 2019. doi:10.1097/00022744-199706000-00003.